Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Efavirenz 600 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction - Oral Contraceptive

NCT00399685
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
San Diego, California • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

Interaction With HIV Antiretroviral Agents

NCT02556268
View directory record Official record
Conditions
HIV-DDI
Interventions
Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Orlando, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Disulfiram Interactions With HIV Medications: Clinical Implications

NCT00878306
View directory record Official record
Conditions
HIV Infections, Drug Abuse
Interventions
Disulfiram, Disulfiram + Efavirenz, Disulfiram + Atazanavir, Disulfiram + Ritonavir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1Phase 2 Interventional

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

NCT00260078
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Results available

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

NCT00414635
View directory record Official record
Conditions
HIV Infections
Interventions
Intermitent Dosing
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Results available

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/zidovudine, Efavirenz, Raltegravir
Drug
Lead sponsor
Westat
Other
Eligibility
16 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics

NCT00668395
View directory record Official record
Conditions
HIV
Interventions
Efavirenz
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Results available

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

NCT00442962
View directory record Official record
Conditions
HIV Infections
Interventions
Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz

NCT01472380
View directory record Official record
Conditions
Healthy
Interventions
efavirenz, fenofibric acid 105 mg
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 4 Interventional Results available

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

NCT00084136
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine (enteric-coated), Efavirenz, Emtricitabine, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine/Zidovudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
27
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

NCT00752856
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Isentress, Atripla
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)

NCT01867996
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban, EFZ 600 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 3 Interventional

A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen

NCT00135343
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanvir/ritonavir + efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
15
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlantis, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, ABC/3TC, Third Antiretroviral Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2012 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 2 Interventional Results available

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

NCT01276236
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414
View directory record Official record
Conditions
Tuberculosis
Interventions
PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r), Rifampin (RIF)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 28, 2026, 7:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label DDI Study of Omaveloxolone in Healthy Subjects

NCT05909644
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Efavirenz
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 28, 2026, 7:12 PM EDT